

1 Supplemental Figures:

2 Figure 1: *Vav3* and *AR3* (*AR-V7*) are critical for proliferation of CRPC cells

3 CWR-R1 cells stably expressing either plk0.1-shGFP, -shVav3, -shAR3 or -shAR were plated at 20,000
4 cells/well in 24 well dishes in 10% FBS. Cells were harvested and counted on three separate days. A
5 representative experiment of three experiments was performed in sextuplicate and data are plotted as cell
6 number (thousands) \pm SEM.

7 Figure 2: *Vav3* and *AR3* (*AR-V7*) drive ligand-independent AR activity in CRPC

8 A, 22Rv1 or B, CWR-R1 cells stably expressing either shGFP, shVav3, or shAR3 were transfected with
9 reporter plasmid PSA-Luc. Luciferase activity was determined 48 h after transfection. Data represent
10 three experiments performed in triplicate and are plotted (fold induction \pm SEM) with shGFP set as one.
11

12 Figure 3: *Vav3* enhances *AR3* (*AR-V7*) transcriptional activity in a PH domain independent manner
13 AR negative human prostate cancer cell line PC3 was transfected with AR or AR3, reporter plasmid
14 ARE-Luc, a Vav3 mutant lacking the PH domain (Δ PH) or equivalent amounts of the corresponding
15 empty vector (EV). Cells were treated with either vehicle (–) or 1nm R1881 (+). Luciferase activity was
16 determined 48 h after transfection. Data represent one of three experiments performed in triplicate
17 plotting the mean RLU/protein \pm SEM. Significance was determined using a two-tailed Student's *t* test
18 (*, $p < .05$).

19 Figure 4: *Vav3* interacts with *AR3* (*AR-V7*) but poorly with wild type AR

20 HEK293 cells were transfected with Vav3-myc and AR or AR3 and harvested 48 hours later. Co-
21 immunoprecipitation was performed as described in *Materials and Methods* using antibodies to mouse
22 (M), rabbit (R), IgG (control), myc, or AR (N-terminal AR, AR-N20). Equivalent volumes were
23 immunoblotted and probed for N-terminal AR and myc. A representative blot of four independent
24 experiments is shown.

25

26 Figure 5: *Vav3* regulates nuclear levels of *AR3* (*AR-V7*)

27 22Rv1 cells stably expressing tet-shGFP or tet-shVav3 were grown in 5% CSS \pm 1ug doxycycline for 72
28 hours. A, Equivalent amounts of total cellular protein were immunoblotted for N-terminal AR and actin.
29 B, Cells were fractionated and immunoblotted for N-terminal AR, histone and SOD as described in
30 *Materials & Methods*. Protein levels were normalized to SOD (cytoplasmic fraction), histone (nuclear
31 fraction) or actin (input). Protein levels were determined from three independent experiments and
32 represent the ratios of doxycycline to untreated cells and are compared to the tet-shGFP treated/untreated
33 values (set to one). Significance was determined using a two-tailed Student's *t* test comparing
34 (treated/untreated) of the experimental group to (treated/untreated) tet-shGFP. C, 22Rv1 cells stably
35 expressing Vav3-FLAG or FLAG were grown in 5% CSS for 72 hours. Equivalent amounts of total
36 cellular protein were immunoblotted for N-terminal AR and actin. D, Nuclear and cytosolic fractions




37 from the same cells were immunoblotted for N-terminal AR, Histone, and SOD. Densitometry was
38 performed on blots from three independent experiments.

39 Figure 6: *Vav3 regulates AR3 recruitment to UBE2C enhancer 2*



40 22Rv1 cells stably expressing shGFP, shAR3, or shVav3 were grown in 5% CSS phenol red free media
41 for 72 hours. Chromatin immunoprecipitation was performed as described in Materials and Methods.
42 Data represent three independent experiments and are plotted as (% input relative to IgG control \pm SEM).

43


Supplemental Figure 1




Supplemental Figure 2





Supplemental Figure 3





Supplemental Figure 4





Supplemental Figure 5A





Supplemental Figure 5B



Supplemental Figure 5C



Supplemental Figure 5D



Supplemental Figure 6

